Our firm represented identifAI Genetics in its initial public offering (IPO) on the Australian Securities Exchange. The representation included a share swap (reverse flip), pre-IPO capital raisings, a commercial agreement in the U.S. required as a condition for the IPO, and service as Israeli legal counsel for the Australian offering. The company is developing a non-invasive prenatal test that enables full fetal DNA mapping via a maternal blood sample.
October 26, 2026